Category Archives: supplements online

images (5)

mix lidocaine with testosterone

Marked reduction of blood pressure, shock, stupor, bradycardia, disturbance of water and electrolyte balance, renal failure, temporary hyperventilation, tachycardia, palpitations, dizziness, anxiety and cough. Treatment: The patient should be placed in intensive care, with careful monitoring serum electrolytes and creatinine. To reduce the absorption of the drug must gastric lavage purpose adsorbents and sodium sulfate for 30 minutes after administration of fosinopril. In the case of significant decrease of blood pressure put a patient with raised feet on the bed and make a rapid intravenous mix lidocaine with testosterone administration of 0.9% sodium chloride solution in / in the introduction of catecholamines. In severe bradycardia – atropine sulfate, in some cases, it may require the use of an artificial pacemaker.

The interaction with other drugs
Diuretics, ethanol, nitroglycerin, other nitrates and vasodilators fosinopril enhance the antihypertensive effect of the drug.
With simultaneous use of drugs with potassium fosinopril, heparin, potassium-sparing diuretics (including with amiloride, spironolactone, triamterene), with additives to foods containing potassium, increases the risk of hyperkalemia, especially in patients with heart failure and diabetes.
Concomitant use of antacids (including aluminum hydroxide, magnesium hydroxide, simethicone), may reduce the absorption  inhibitor.
in the application  inhibitors of the enzyme with drugs lithium may reversible increase in the concentration of lithium in blood plasma and, accordingly, increase the risk of its toxic effects.
reduce the antihypertensive effect  inhibitors, rendering thus a synergistic effect on the increase of potassium in the blood plasma, but also can cause renal dysfunction.
Simultaneous use inhibitors and drugs that reduce the concentration of glucose in the blood (insulin, hypoglycemic agents for oral administration) may cause a further decrease in the concentration of glucose in blood and the risk of hypoglycemia, particularly in the first weeks of treatment and in patients with renal insufficiency.
Simultaneous use of certain tricyclic antidepressants, antipsychotics agents, anesthetics (including opioid analgesics and drugs for general anesthesia) inhibitors may result in further reduction of blood pressure and the development of orthostatic hypotension,
Sympathomimetics reduce the antihypertensive effect  inhibitors. While the use of immunosuppressants, cytotoxic drugs: corticosteroids for systemic use, allopurinol and procainamide, there is a risk of leucopenia.
Fosinopril may understate the rates of serum digoxin concentrations.

Before using the and during the reception should be carefully monitored blood pressure, renal function, the number of blood cells, the potassium content, the concentration of creatinine and glucose in the blood serum.
In just a few days before the start of therapy  spent earlier antihypertensive treatment should be discontinued.
patients with severe chronic heart failure III and IV functional class mix lidocaine with testosterone classification, as well as patients of other risk groups, treatment should be started under medical supervision.
patients with impaired water and electrolyte balance recommended the correction of water and electrolyte abnormalities prior to treatment , patients treated with insulin or hypoglycemic agents for oral administration, while taking  inhibitors need to monitor the concentration of glucose in the blood, especially during the first month of use.
if conditions accompanied by a decrease in the bcc (diuretics, salt-free diet, vomiting, diarrhea, hemodialysis), reninzavisimoy hyponatremia, cerebrovascular disease, ischemic heart disease increases the risk of a sharp decline in blood pressure, If renovascular hypertension, bilateral renal artery stenosis or stenosis of the artery only functioning kidney is increased risk of severe hypotension and pitting failure.Also, during treatment with mix lidocaine with testosterone inhibitors may increase the concentration of urea nitrogen and serum creatinine. These effects usually occur in patients with renal insufficiency, they are reversible and disappear after cessation of treatment.
At the systemic connective tissue diseases (systemic lupus erythematosus, scleroderma) and therapy of immunosuppressants (including after kidney transplantation) increases the risk of neutropenia, agranulocytosis.
When hyperkalemia. stenosis of the aortic valve, hypertrophic obstructive cardiomyopathy, heart failure III and IV functional class  classification, for the treatment of hypoglycemic agents in patients at risk of hypoglycaemia increases with diabetes.
In patients receiving mix lidocaine with testosterone inhibitors may increase potassium in the blood serum, in patients at risk hyperkalemia, namely in patients with renal insufficiency, uncontrolled diabetes mellitus, host kaliysberegayushie diuretics, potassium supplements or other drugs, the reception of which can lead to an increase of serum potassium (eg heparin), may cause hyperkalemia.
in hemodialysis using vysokoprotochnyh poliakrilnitrilozyh membrane plasmapheresis with the use of dextran sulfate in patients with elevated low-density lipoprotein, as well as the specific desensitisation to bee venom increases the risk of allergic reactions.

Без названия

mix testosterone propionate powder

Pregnancy and lactation
The drug-Fosinopril Teva is contraindicated in pregnancy. The use inhibitors in the II and III trimester of pregnancy causes damage or even death of the developing fetus. In identifying pregnancy fosinopril treatment should be discontinued immediately. For infants whose mothers took mix testosterone propionate powder inhibitors during pregnancy, careful monitoring is recommended for early detection of arterial hypotension, oliguria and hyperkalemia.
Since fozinoprilat excreted in breast milk, if necessary, use Teva-Fosinopril should stop breastfeeding.

Inside. The tablet is swallowed, without chewing, with a glass of water, regardless of the meal, preferably at the same time.
If you forget to receiving one or more doses of the drug to the next reception-Fosinopril Teva should be taken at the usual dose; take a higher dose should not be. Hypertension. The recommended starting dose is 10 mg 1 time per day. Then the dose is adjusted depending on the dynamics of lowering blood pressure; in the absence of the desired therapeutic effect within 3-4 weeks, the dose can be increased.Maintenance doses ranging from 10 mg up to a maximum dose of 40 mg 1 time per day. With the use of  inhibitors in patients receiving diuretic therapy, may experience a sharp drop in blood pressure, which is recommended for the prevention stop taking diuretics 2-3 days before the expected start of fosinopril therapy. If unable to cancel the diuretics mix testosterone propionate powder should be used in an initial dose of 10 mg 1 once a day. Patients with high activity of the (especially in patients with renovascular hypertension, disorders of water and epektrolitnogo balance, decompensated heart failure, or severe hypertension) because of the possibility of a sudden drop in blood pressure treatment with Fosinopril-Teva is recommended to start under a doctor’s supervision. Chronic heart failure. The recommended starting dose is 1 to 10 mg once a day. Starting treatment should be supervised by a doctor. With good endurance increase the dose at weekly intervals, increasing it to 40 mg 1 time per day. For the treatment of chronic heart failure drug-Fosinopril Teva is usually combined with a diuretic and, if necessary, cardiac glycosides. Elderly patients are differences in the efficacy and safety of drug treatment in elderly patients aged 65 years or older and younger patients are not observed. However, we can not exclude a great sensitivity in some elderly patients to the drug, due to the possible effects of an overdose due to delayed elimination of fosinopril, in patients with impaired renal function or hepatic reduction in dose-Fosinopril Teva is not usually required.

Side effects:
The frequency of side effects is classified in accordance with the recommendations : very often-not less than 10%; often – at least 1% but less than 10%; infrequently – at least 0.1% but less than 1%: rare – less than 0.01% but less than 0.1%; very rare (including isolated cases) – less than 0.01%, the part of the hematopoietic system and lymphatic system: rarely – transient decrease in hemoglobin or hematocrit; rarely – eosinophilia, leukopenia, thrombocytopenia, neutropenia, lymphadenopathy; very rarely – agranulocytosis. On the part of metabolism: rarely – decreased appetite, current worsening of gout, hyperkalemia. On the part of the central nervous system: often – dizziness, headache; rarely – depression, paresthesia, somnolence, stroke, cerebral ischemia, tremor, insomnia, taste disturbances; seldom – a speech disorder, memory impairment, confusion, disorientation. From a sight organ: seldom-visual disturbances.

On the part of the organ of hearing, and the vestibular system:rarely – ringing in the  mix testosterone propionate powderears, ear pain, dizziness. Cardio-vascular system: often – tachycardia, marked reduction in blood pressure, orthostatic hypotension; rarely – angina, myocardial infarction, palpitations, cardiac arrest, arrhythmia, increased blood pressure, peripheral edema; rarely – “tides” of blood to the skin of the face, bleeding, the peripheral blood circulation. The respiratory system: often – dry cough;rarely – dyspnea, rhinitis, pharyngitis, bronchitis; rarely – bronchospasm, pneumonia, pulmonary infiptraty. On the part of the digestive tract: often – nausea, vomiting, diarrhea; rarely – constipation, dryness of mucous membranes of the mouth, flatulence; rarely – stomatitis, pancreatitis, angioneurotic edema, tongue, dysphagia, abdominal pain; very rarely – angioneurotic edema of the bowel, bowel obstruction. On the part of the liver and biliary tract: rarely – hepatitis; rarely -pechenochnaya failure. Skin and subcutaneous tissue disorders: often – skin rash, angioedema, dermatitis; Infrequent – increased sweating, itching, hives; rarely -. hemorrhages in the skin (ecchymosis) syndrome has been described. include fever, vasculitis, muscle pain, joint pain or arthritis, antinuclear antibodies, increased erythrocyte sedimentation rate, eosinophilia and leukocytosis, rash, photosensitivity and other cutaneous manifestations. From the musculoskeletal system: rarely – myalgia; -artralgiya rarely arthritis. From the urinary system: rarely – proteinuria, development or exacerbation of the symptoms of chronic renal failure, disorders of the prostate gland; rarely – acute interstitial nephritis; rarely, acute renal failure. Reproductive system: rarely – impotence, decreased libido. Other: often – general weakness, pain, unspecified; rarely – fever, sudden death, increased body mass index; rarely – muscle weakness. From the laboratory parameters: often – increased activity of “liver” transaminases, lactate dehydrogenase, and alkaline phosphatase, hyperbilirubinemia; infrequently – hypercreatininemia, increasing concentrations of urea, hyperkalemia; rarely mix testosterone propionate powder – hyponatremia, a slight increase in hemoglobin, Fosinopril may understate the rates of serum digoxin concentrations.

su 250 testosterone mix

After oral absorption from the gastrointestinal tract su 250 testosterone mix is about 30-40% degree of absorption is independent of food intake, but the rate of absorption may be delayed. The fast and practically complete hydrolysis to form the pharmacologically active mucosal occurs fozinoprilata liver and small intestine. One hour after ingestion concentration fosinopril unaltered serum – less than 1%. fozinoprilata – 75% inactive glucuronide fozinoprilata – 15-20%, active metabolite 4-gidroksifozinoprilata-about 5%.

The maximum concentration fozinoprilata plasma levels achieved in 3 hours and is independent of the dose. Distribution and metabolism. Binding plasma proteins is greater than 95%. Therefore fozinoprilat has a relatively small volume of distribution and to a small extent with the associated cellular components of blood. Excretion. Fozinoprilat excreted equally excreted by the kidneys and in the intestine. When hypertension in patients with normal renal function, and hepatic elimination half-life  fozinoprilata is about 11.5 hours. In heart failure, increased to 14 hours. In patients with impaired renal function fozinoprilata total clearance from the body about two times lower than in patients with normal renal function. At the same time, the absorption, bioavailability, and protein binding is not significantly changed.Decreased renal excretion is compensated by an increased excretion by the liver. Moderate increase in the area of values under the curve “concentration-time  fozinoprilata plasma (less than half compared to the norm) was observed in patients with renal impairment of varying degrees, including renal failure, end-stage .

The clearance fozinoprilata in hemodialysis and peritoneal dialysis averages 2% and 7% (in relation to the values of urea clearance). in patients with impaired hepatic function (in alcoholic or biliary cirrhosis) a significant change in the degree of hydrolysis fosinopril does not, however, possible to reduce the rate of occurrence of this biochemical reaction. The total su 250 testosterone mix clearance fozinoprilata from the body of these patients is approximately twice lower than in patients with normal liver function. in men aged 65 to 74 years with clinically normal renal and hepatic function noticeable differences fozinoprilata pharmacokinetic parameters compared with younger patients (20-35 years old) is not observed.



  • Arterial hypertension;
  • Chronic heart failure (in combination therapy).Contraindications
    : Hypersensitivity to fozinoprigu, other ingredients and other  inhibitors; angioedema in history (hereditary, idiopathic or associated with the use of su 250 testosterone mix inhibitors); pregnancy: breastfeeding; age of 18 years; lactose intolerance, lactase deficiency. gapaktoznaya glucose malabsorption.

    Concomitant use with diuretics, nitrates, vasodilators. potassium drugs, heparin, potassium-sparing diuretics, antacids, drugs lithium, nonsteroidal anti-inflammatory , insulin, hypoglycemic agents for oral, tricyclic antidepressants, antipsychotics, opioid analgesics, drugs for general anesthesia, immunosuppressive agents, sympathomimetics, cytostatics, corticosteroids , procainamide, allopurinol; Chronic heart failure  functional class  classification; state, accompanied by a decrease in circulating blood volume su 250 testosterone mix; Coronary heart disease su 250 testosterone mix; cerebrovascular diseases: hypertension, renovascular; bilateral renal artery stenosis; stenosis of the artery to a solitary kidney; systemic connective tissue diseases (scleroderma, systemic lupus erythematosus);hyperkalemia; stenosis of the aortic valve; hypertrophic obstructive cardiomyopathy: uncontrolled diabetes; hemodialysis; plasmapheresis; when desensitization or desensitization procedures; inhibition of bone marrow hematopoiesis, old age, condition after kidney transplantation.